Axovant Sciences Ltd., of Basel, Switzerland, said it priced its underwritten public offering of 30 million of its common shares at $1 each with gross proceeds expected to be approximately $30 million. The underwriters have been granted a 30-day option to purchase up to an additional 4.5 million shares on the same terms and conditions.